Aligos Therapeutics Inc. (ALGS)
ALGS trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1799448/000119312526092614/0001193125-26-092614-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ALGS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001799448 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $2.2M |
| Net income | -$24.2M |
| Operating income | -$88.0M |
| Net margin | -1106.7% |
| Operating margin | -4024.9% |
| Revenue growth | -39.5% |
| Cash | $18.3M |
| Total assets | $88.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Our current operating plan and projected cash outflows for the upcoming periods raise substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements included elsewhere in this Quarterly Report." | 10-Q 2026-11-06 |
| Cash and burn | $31.1M cash; operating cash flow -$17.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 12,496,956 (2026-11-03). | Cover page 2026-11-03 |
| Reverse splits, 3 years | 1; latest 1-for-25 on 2024-08-19 | Source 2024-08-19 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Francisco, California, United States | PCAOB Form AP 2026-03-23 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
| Market cap check | The listing's market cap implies 6,248,478 shares at the 2026-11-13 price; the latest SEC cover count is 12,496,956 as of 2026-11-03. One of the two share counts is stale. | Nasdaq screener and SEC cover page |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $2.8M | -$21.9M | $1.5M | $31.1M | No debt tags | $5.8M | 10-Q 2026-11-06 |
| Q2 2026 2026-06-30 | $0 | -$1.5M | -$24.9M | $30.4M | No debt tags | $3.7M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $2.8M | -$23.0M | -$23.1M | $30.0M | No debt tags | $4.7M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $169K | -$19.9M | -$21.7M | $18.3M | No debt tags | $2.2M | 10-K 2026-03-05 |
| Q3 2025 2025-09-30 | $741K | -$31.5M | -$24.3M | $41.9M | No debt tags | $2.6M | 10-Q 2026-11-06 |
| Q2 2025 2025-06-30 | $965K | -$15.9M | -$15.5M | $18.7M | No debt tags | $3.1M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $311K | $43.1M | -$20.9M | $73.8M | No debt tags | $3.2M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $606K | -$82.2M | -$18.4M | $37.0M | No debt tags | $3.6M | 10-K 2026-03-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.
Price moves
| Window | Return |
|---|---|
| 1 week | -48.4% |
| 1 month | -61.9% |
| 3 months | -69.0% |
| Year to date | -77.5% |
| 1 year | -65.4% |
| From 52-week high | -84.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| INTS | Intensity Therapeutics Inc. | $3.07 | -0.32% | $10.1M |
| SCLX | Scilex Holding Company | $1.25 | -12.59% | $10.6M |
| TCRX | TScan Therapeutics Inc. | $0.1451 | -9.65% | $9.2M |
| BCDA | BioCardia Inc. | $0.7901 | -4.92% | $12.0M |
| INAB | IN8bio Inc. | $0.8160 | -0.49% | $8.8M |
| DYAI | Dyadic International Inc. | $0.3200 | -2.14% | $12.8M |
| JSPR | Jasper Therapeutics Inc. | $11.77 | -13.96% | $13.1M |
| PASG | Passage Bio Inc. | $4.13 | -2.82% | $13.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier